Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for Atrial Fibrillation Burden in Overweight/Obese Patients
NCT05209165Phase 4Suspended
- Sponsor
- San Francisco VA Medical Center
- Start
- May 2023
- Primary completion
- May 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of semaglutide in Atrial fibrillation (AFib), sponsored by San Francisco VA Medical Center. Started May 2023; status: suspended.
02
Drugs
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT05209165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05209165.